Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent

Executive Summary

ODYSSEY outcomes study homes in on value of PCSK9 inhibition for the subgroup of patients with LDL of at least 100 mg/dL, a potentially large market, but how much will payers ease restrictions in exchange for a lower price?

Advertisement

Related Content

PCSK9 Pick-Me-Up: New Cholesterol Guidelines May Mean Lower LDL Targets
Esperion Aims Low On Price For Cholesterol Drug Bempedoic Acid
Ex-US FDA Director John Jenkins Sketches Regulatory Path For Esperion's Bempedoic Acid
Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It
PCSK9 Add-On Study Helps Esperion Cover All The Bases With Bempedoic Acid
Praluent Pricing: Collaboration With ICER Sets A New Standard
Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Amgen Focuses On Pipeline As Mature Products Face Declining Demand
Amgen Faces New ICER Roadblock To Repatha Reimbursement
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100557

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel